Read More Pharma Industry News Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate… bypharmanewsdailyOctober 15, 2018
